DDIT4 and neoplasm: With regard to glioblastoma-associated signaling, metformin may interfere with AMPK activity, which in turn modulates (suppression) mTOR signaling relevant for tumor growth and invasion, as regulated during tumor development via the DNS damage response (REDD1) pathways and oxidative stress (Figure 1) [61].